Skip to main content
Premium Trial:

Request an Annual Quote

Illumina: Alex Aravanis, Mostafa Ronaghi

Illumina announced that Alex Aravanis will join the company in June as Chief Technology Officer. He will be responsible for leading the firm's R&D functions as well as translation of next-generation sequencing into the clinic. He will report to CEO Francis deSouza.

Aravanis returns to Illumina from Grail, where he was chief scientific officer and head of R&D; he was also a cofounder. At Grail, he led development of that firm's multi-cancer early detection test. While at Illumina, he developed clinical assays and bioinformatic pipelines for the analysis of RNA and DNA from fixed tissues, whole-exome analysis, massively parallel single-cell transcriptomics, and liquid biopsy using cell-free nucleic acids. He holds both an MD and a doctorate in electrical engineering from Stanford University.

Aravanis will replace current CTO Mostafa Ronaghi, whom Illumina has appointed to lead global entrepreneurial development. Ronaghi is also a Grail cofounder and launched the Illumina Accelerator program in 2014, and was recently appointed to Grail's board of directors.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.